Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | GAA | P10253 | 5/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | GLA | P06280 | 2/20 | 0.56 |
| ▸ | CASP1 | P29466 | 1/20 | 0.56 |
| ▸ | CASP7 | P55210 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | CFTR | P13569 | 4/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2897750 | 0.90 | KDM4E (0.61) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL27501597 | 0.88 | KDM4E (0.59) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL4758833 | 0.87 | KDM4E (0.73) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL25369023 | 0.86 | KDM4E (0.58) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL274700 | 0.86 | KDM4E (0.55) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL3899027 | 0.85 | KDM4E (0.77) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL17030839 | 0.85 | ABL1 (0.57) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL12021071 | 0.85 | KDM4E (0.56) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL15131701 | 0.85 | KDM4E (0.56) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL3616519 | 0.85 | KDM4E (0.56) | KDM4EALDH1A1GAAHSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12338240-B2 | Nonmuscle myosin ii inhibitors | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250163056-A1 | NONMUSCLE MYOSIN II INHIBITORS | THE UNIV OF FLORIDA RESEARCH FOUNDATION INC (US) | 2025-05-22 | — | — | US | disclosed |
| WO-2025101598-A1 | BI-CYCLIC PYRIMIDINE COMPOUNDS, METHODS AND USES THEREOF | ZENO MANAGEMENT, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230227452-A1 | NONMUSCLE MYOSIN II INHIBITORS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230227452-A1 | NONMUSCLE MYOSIN II INHIBITORS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| WO-2023133217-A1 | 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES | REMIX THERAPEUTICS INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| US-11649234-B2 | Nonmuscle myosin II inhibitors for substance use relapse | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649234-B2 | Nonmuscle myosin II inhibitors for substance use relapse | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649234-B2 | Nonmuscle myosin II inhibitors for substance use relapse | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-7002022-B2 | N-Aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF | NOVARTIS AG (CH) | 2006-02-21 | — | — | US | disclosed |
| US-6878720-B2 | VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2005-04-12 | — | — | US | disclosed |
| WO-2005007634-A1 | 3-HYDROXY-4-OXO-1,2,3-TRIAZINES AND DERIVATIVES THEREOF FOR AMIDE AND ESTER BOND FORMATION | FRUTAROM LTD. (IL) | 2005-01-27 | — | — | WO | disclosed |
| US-20040198782-A1 | N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ (CH) | 2004-10-07 | — | — | US | disclosed |
| US-20030064992-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ (CH) | 2003-04-03 | — | — | US | disclosed |
| US-6448277-B2 | ANTITUOR AGENTS, ANTICARCINOGENIC AGENTS | NOVARTIS AG (CH) | 2002-09-10 | — | — | US | disclosed |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2002-02-14 | — | — | US | disclosed |
| EP-1129075-A1 | N-ARYL(THIO)ANTHRANILIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000027820-A1 | N-ARYL(THIO)ANTHRANILIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2000-05-18 | — | — | WO | disclosed |
| US-4276295-A | VASODILATORS, HYPOTENSIVE, ANTIATHEROSCLEROTIC | Ishikawa, Masayuki (JP) | 1981-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030857-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A4, SLC2A2 | KDM4E 2325/4885ALDH1A1 1422/4885GAA 332/4885 |
| US-20250163056-A1 | NONMUSCLE MYOSIN II INHIBITORS | MYH2, MYO3B, MYO1B | KDM4E 3550/4885ALDH1A1 2712/4885GAA 1004/4885 |
| US-20030064992-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, NR2E3 | KDM4E 3338/4885ALDH1A1 2918/4885GAA 3455/4885 |
| US-20230227452-A1 | NONMUSCLE MYOSIN II INHIBITORS | MYH2, MYO3B, MYO1B | KDM4E 3550/4885ALDH1A1 2712/4885GAA 1004/4885 |
| US-12338240-B2 | Nonmuscle myosin ii inhibitors | MYH2, MYO3B, MYO1B | KDM4E 3550/4885ALDH1A1 2712/4885GAA 1004/4885 |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, KDR | KDM4E 3319/4885ALDH1A1 2909/4885GAA 3029/4885 |
| US-20040198782-A1 | N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, NR2E3 | KDM4E 3302/4885ALDH1A1 3031/4885GAA 3440/4885 |
| US-11649234-B2 | Nonmuscle myosin II inhibitors for substance use relapse | MYH2, MYO3B, MYO1B | KDM4E 3535/4885ALDH1A1 1902/4885GAA 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.